Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
After a phase 3 push the livmoniplimab plan falters.
The company discontinues one of its two KRAS G12D degraders.
With a slashed valuation the newly listed biotech heads for phase 3.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
